Depo-Provera Lawsuit 2026: Brain Tumor Claims, Who Qualifies & Latest MDL Updates

What is Depo-Provera?

Depo-Provera is the brand name for an injectable hormonal contraceptive containing medroxyprogesterone acetate (MPA), a synthetic progestin administered as an intramuscular injection once every three months. Manufactured by Pfizer, it has been available in the United States since FDA approval in 1992 and is used by approximately 3.5 million American women annually.

The drug works by suppressing ovulation, thickening cervical mucus, and thinning the uterine lining, making it one of the most effective reversible contraceptives on the market with a failure rate under 1% when administered on schedule. Beyond contraception, Depo-Provera is also prescribed for endometriosis pain management, uterine fibroids, and certain hormone-sensitive cancers.

For decades, Depo-Provera's prescribing information listed bone density loss as a notable long-term risk, prompting the FDA to add a black box warning in 2004. Consulting pharmaceutical litigation firm can help evaluate your specific claim. What that label has never disclosed (and what now sits at the center of thousands of lawsuits) is a statistically significant elevation in the risk of meningioma brain tumors associated with prolonged MPA use. Related: latest Depo-Provera lawsuit updates.

The Science: Depo-Provera and Meningioma Risk

Meningiomas are the most common primary brain tumors in adults, arising from the meninges, the three-layer membrane enveloping the brain and spinal cord. While roughly 90% are classified as benign (WHO Grade I), their physical location within the skull means even non-malignant tumors can cause severe neurological complications: debilitating headaches, vision loss, seizures, hearing impairment, memory dysfunction, and partial paralysis, depending on the tumor's site and growth rate.

The 2023 French Cohort Study, The Pivotal Finding

The scientific cornerstone of this litigation is a landmark cohort study published in the British Medical Journal (BMJ) in 2023, analyzing data from France's national health insurance database covering over 100,000 women. The researchers found that prolonged use of MPA-based injectable contraceptives was associated with a fivefold to sevenfold increase in meningioma incidence compared to non-users, a finding that holds up after controlling for age, prior hormone therapy, and other known meningioma risk factors.

Critically, the study found a clear dose-response relationship: the longer a woman used MPA injections, the higher her relative risk. Women who used Depo-Provera for five or more years showed the highest tumor incidence rates, lending strong causal support to the hypothesis that MPA (not unrelated demographic factors) was driving the elevated risk.

The 2024 Meta-Analysis, Confirmation Across Four Countries

A 2024 meta-analysis published in Neurological Sciences pooled data from seven independent studies conducted across France, the United Kingdom, Denmark, and the United States. The analysis concluded that MPA exposure was "significantly and independently associated" with meningioma development, with a pooled relative risk ratio of approximately 4.8, meaning long-term Depo-Provera users are nearly five times more likely to develop meningiomas than non-users.

This degree of statistical consistency across independent research groups in multiple countries is considered highly probative in pharmaceutical litigation, because it substantially diminishes alternative explanations and supports the core causation argument plaintiffs must establish to win their cases.

What Was Pfizer Required to Do?

Under federal pharmaceutical law (21 C.F.R. § 201.57), drug manufacturers are required to update their prescribing labels to reflect newly discovered serious risks in a timely manner. Regulatory experts cited in numerous Depo-Provera lawsuits argue that the MPA-meningioma signal was identifiable in earlier epidemiological data long before the 2023 BMJ publication, and that Pfizer had both the legal duty and the scientific basis to update the Depo-Provera label years earlier. The failure to do so forms the core of every failure-to-warn claim in the litigation.

Lawsuit Background & Legal Basis

Mass tort litigation against Pfizer over Depo-Provera's alleged meningioma risk began accelerating through 2024 in the wake of widespread coverage of the BMJ study findings. By early 2025, plaintiff attorneys had filed hundreds of individual lawsuits in federal courts across multiple jurisdictions, prompting the Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federally filed cases before a single judge for coordinated pre-trial proceedings.

Legal Theories Plaintiffs Are Asserting

Attorneys representing Depo-Provera plaintiffs are advancing several overlapping legal claims, all of which center on Pfizer's failure to disclose the meningioma risk:

• Failure to warn, Pfizer knew or should have known about the meningioma risk and failed to update the Depo-Provera prescribing label to warn physicians and patients. Drug manufacturers carry a continuing duty to update labeling as new safety data emerges.
• Negligence, Pfizer failed to conduct adequate post-market surveillance of MPA's long-term neurological effects and ignored epidemiological signals present in European medical literature for years before the 2023 BMJ publication.
• Strict products liability, The product was unreasonably dangerous given its undisclosed meningioma risk, making Pfizer liable regardless of fault under strict liability doctrine adopted in most U.S. jurisdictions.
• Fraudulent misrepresentation, Marketing materials actively promoted Depo-Provera as safe and well-tolerated without disclosing the brain tumor risk, constituting actionable misrepresentation to both prescribing physicians and patients.
• Breach of warranty, Express and implied warranty claims based on Pfizer's failure to disclose material safety information in the drug's labeling, which constitutes the basis of any implied warranty of fitness for ordinary contraceptive use.

MDL Status & 2026 Case Updates

The Depo-Provera meningioma cases are proceeding as a federal multidistrict litigation (MDL), a procedural consolidation mechanism that coordinates discovery, Daubert expert hearings, and pre-trial motions across thousands of individual lawsuits without merging them into a single class action. Each plaintiff retains her individual case and potential for independent compensation.

As of June 2026, the MDL includes over 8,000 active plaintiffs, with new cases being filed weekly. Legal analysts tracking pharmaceutical MDLs project the total claimant population could exceed 25,000 before a global resolution is reached, based on the known volume of long-term Depo-Provera users and meningioma diagnosis rates in that population.

Notably, the French medical regulatory authority (ANSM) has already taken regulatory action, ordering manufacturers to add meningioma warnings to MPA labels in France in 2023. U.S. plaintiff attorneys cite this as evidence that the risk was scientifically established and industry-acknowledged well before Pfizer updated U.S. labeling.

Who Qualifies to File a Depo-Provera Claim?

Eligibility for a Depo-Provera lawsuit is evaluated case-by-case by mass tort attorneys based on medical records, usage history, and the nature of the injury. The following criteria reflect the general benchmarks recognized across the MDL as of mid-2026:

Core Eligibility Requirements

• Depo-Provera use history: Receipt of Depo-Provera (medroxyprogesterone acetate 150mg/mL injection) or a generic equivalent for a minimum of approximately 12 consecutive months. Cases involving two or more years of continuous use are generally considered stronger because the dose-response relationship is better established at longer durations.
• Confirmed meningioma diagnosis: A documented medical diagnosis of meningioma (any grade) confirmed via MRI, CT scan, or biopsy. Cases involving larger tumors (greater than 3 cm), multiple meningiomas, atypical or malignant classifications (Grade II or III), or tumors requiring surgical removal carry substantially higher case values.
• Temporal relationship: The meningioma diagnosis should bear a plausible causal timeline to Depo-Provera use, typically diagnosed during active treatment or within several years post-cessation, consistent with the latency periods documented in the French and other studies.
• No prior brain tumor history: Pre-existing meningioma diagnoses or high-risk genetic conditions such as neurofibromatosis type 2 may complicate causation arguments and affect case strength.
• Age and health status: Younger women at the time of use who developed meningiomas (when their baseline risk would otherwise be low) present particularly compelling cases given the statistical anomaly their diagnosis represents.

Expected Settlement Value & Compensation

Because the Depo-Provera MDL is still in its early pre-trial phase as of 2026, no global settlement fund or official payout matrix has been announced. However, pharmaceutical litigation history and the severity of injuries alleged provide a basis for preliminary estimates.

Factors That Influence Individual Case Value

Mass tort attorneys and litigation analysts typically evaluate Depo-Provera case value based on the following factors:

Preliminary Compensation Estimates

Based on comparable pharmaceutical MDL outcomes, including the Taxotere permanent hair loss MDL, the Zantac litigation, and similar mass torts, legal analysts tracking the Depo-Provera cases have offered preliminary individual case value ranges:

• Watch-and-wait / low-grade incidental cases: $50,000 – $150,000
• Symptomatic tumors requiring surgical removal: $250,000 – $750,000
• Surgery with significant neurological complications: $750,000 – $2,500,000
• Severe permanent disability / Grade II–III tumors: $2,000,000 – $5,000,000+

These ranges are illustrative projections, not guaranteed outcomes. Actual settlements will depend on total MDL resolution terms, the number of qualifying claimants, and Pfizer's ultimate litigation strategy. Bellwether trial results (expected in 2027) will be the primary driver of settlement negotiations.

How to File a Depo-Provera Lawsuit Claim

Filing a Depo-Provera claim in the MDL is a straightforward process when guided by an experienced mass tort attorney. Here is the step-by-step pathway most plaintiffs follow:

1. Gather your medical records. Collect documentation of your Depo-Provera injection history (pharmacy records, gynecological records, insurance EOBs), your meningioma diagnosis (MRI/CT imaging reports, biopsy pathology), and any records of treatment received. Your attorney can help subpoena records you cannot obtain directly.
2. Contact a mass tort attorney for a free case evaluation. Most firms handling Depo-Provera cases offer free, no-obligation consultations. They will assess your usage history, diagnosis, and injury to determine whether you have a qualifying claim. This evaluation typically takes 20–30 minutes and can be completed by phone.
3. Sign a contingency fee agreement. Mass tort attorneys work on a contingency fee basis, meaning you pay zero legal fees unless your case resolves in a settlement or verdict. Standard contingency fees in MDL pharmaceutical cases range from 33%–40% of the gross recovery, negotiated with your attorney upfront.
4. Your case is filed and enrolled in the MDL. Your attorney will file your complaint in the appropriate federal court. The case will then be transferred to the MDL for coordinated pre-trial proceedings with thousands of other plaintiffs.
5. Participate in discovery as needed. You may be asked to complete a Plaintiff Fact Sheet (PFS) (a standardized questionnaire detailing your medical and usage history) and potentially provide a deposition. Your attorney manages this process on your behalf.
6. Monitor bellwether trial developments and await settlement. Most mass tort MDLs resolve through negotiated global settlements after bellwether trial verdicts establish case value benchmarks. If a global settlement is reached, you and your attorney will evaluate the offer and decide whether to accept or opt out and proceed to individual trial.

Statute of Limitations, Why You Must Act Promptly

Every Depo-Provera lawsuit is subject to a statute of limitations, the legal deadline by which you must file your claim or permanently lose the right to sue. In pharmaceutical product liability cases, this deadline is governed by state law and typically ranges from two to four years from the date you were diagnosed with a meningioma, or from the date you reasonably discovered (or should have discovered) the connection between Depo-Provera and your tumor.

The "discovery rule", which starts the clock when you knew or should have known about the drug connection, can extend the statute in some circumstances. However, courts interpret this rule narrowly, and given the widespread media coverage of the Depo-Provera-meningioma link since late 2023, arguments that plaintiffs were unaware of the potential connection become harder to sustain with each passing month.

How to Choose the Right Mass Tort Attorney

Not every personal injury attorney has the resources or experience to handle a complex pharmaceutical MDL. Choosing the right legal representation significantly affects both your likelihood of success and the compensation you ultimately receive. Key criteria to evaluate include:

• MDL experience: Look for a firm with documented track records in pharmaceutical MDLs, ideally in cases against major drug manufacturers. Ask specifically whether attorneys on the Depo-Provera Plaintiffs' Steering Committee (PSC) are affiliated with the firm, as PSC members have direct access to case strategy and discovery materials.
• Resources for litigation: Large pharmaceutical cases require significant upfront investment in expert witnesses, medical consultants, and document review. Ensure your attorney's firm has sufficient financial resources to fund your case through trial if necessary.
• Contingency fee structure: Confirm the exact percentage and whether litigation costs (expert fees, filing fees) are advanced by the firm or deducted separately from your recovery. Get this in writing before signing.
• Client communication: MDLs can take several years to resolve. Choose a firm with dedicated case managers and a clear protocol for updating clients on MDL developments, even during periods when individual case activity is low.
• No upfront costs: Reputable mass tort firms never charge upfront fees for case evaluations or filing. Be wary of any firm requesting payment before a settlement is achieved.

For further guidance on selecting a class action or mass tort attorney, see our comprehensive legal guide on attorney selection criteria.